Company news
Shanghai Henlius Biotech, Inc. Class H (HKEX:2696) news
Shanghai Henlius Biotech, Inc. Class H news releases on 6ix. Latest, Sep 30, 2026: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Press releases & updates
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
September 30, 2026
(1) CHANGES IN NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR (2) APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHANGES IN COMPOSITION OF THE BOARD COMMITTEES
September 30, 2026
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
August 21, 2026
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
August 21, 2026
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
August 17, 2026
FDA Approves Shanghai Henlius Biotech IND For Cetuximab Biosimilar
May 28, 2026
Henlius Announces IND Approval from NMPA for Its Proprietary c-Met/EGFR Bispecific ADC HLX48
May 22, 2026
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
April 29, 2026
NMPA Grants IND Approval for Henlius Nivolumab Biosimilar HLX18 Following U.S. FDA Clearance
March 23, 2026
Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
March 20, 2026
Henlius Obtains Japan MAH License Strengthening Presence in the World's Fourth-Largest Pharmaceutical Market
March 2, 2026
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 5, 2026
Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
January 16, 2026
Henlius Fifth U.S. Filing Product Bevacizumab Biosimilar HLX04 Receives FDA BLA Acceptance
January 14, 2026
Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
December 23, 2025
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
November 20, 2025
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
November 17, 2025
Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine
October 22, 2025
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
October 9, 2025
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
September 19, 2025
FUTUONING Sets Sail Commercially with First Prescriptions Across China
September 5, 2025
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
September 2, 2025
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
August 25, 2025
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
July 1, 2025
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
April 29, 2025
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
April 17, 2025
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
April 16, 2025
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
March 24, 2025
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer
March 19, 2025
FDA Accepts BLA For Shanghai Henlius Biotech's HLX11, A Pertuzumab Biosimilar
February 11, 2025
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
February 6, 2025
Shanghai Henlius Biotech, Inc. - US FDA Accepts Biologics License Application for HLX11, Biosimilar Candidate of Perjeta
February 3, 2025